EVAH Announces Acquisition and Development Agreements for Four Technologies from Elanco

This provides EVAH with a diversified portfolio of technologies targeting three species

MONTRÉAL, QUÉBEC (May 25, 2021) – EVAH Corp. (EVAH or the Company) today announced the signing of four contracts with Elanco Animal Health Incorporated (NYSE: ELAN, Elanco) to acquire and develop technologies in animal health. EVAH is a biotechnology company specializing in the development of biologicals to help prevent bacterial diseases in food animals and microbiome solutions for growth performance. 

The four contracts between EVAH and Elanco relate to four products in development (two feed additives and two vaccines) targeting three species: salmon, swine and poultry. EVAH intends to develop the products up to an advanced pre-commercial stage and consult with Elanco throughout the process. Terms of the deal remain confidential but do not involve an equity investment in EVAH from Elanco.

EVAH is focusing on bringing sustainable development of animal health to a new level,” said Michel Fortin, CEO of EVAH. “Leveraging our lab-to-market innovation experience from previous entrepreneurial success, we are now sourcing, acquiring and in-licensing molecules and technologies to develop into valuable products, in order to satisfy major unmet needs in animal health. We proactively sought out Elanco and are very proud to conclude these agreements today.

Elanco’s current collaboration with EVAH originates from the long-standing relationship between the two groups and a belief that we can efficiently work together to drive the development of products to a pre-commercial stage,” said Scott Holmstrom, Vice President, Product Development and Innovation Regulatory. “This is in line with our approach to sustain innovation flow through external partnerships and collaboration and bring our portfolio of products to market,” he added.

EVAH’s management and scientific resources are teaming up again, having previously worked together at Prevtec Microbia. The Company has office and lab facilities in Québec (Montréal, Saint-Hyacinthe and Laval) and Prince Edward Island.

About Elanco 

Elanco is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of experience in animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability/ESG Pledges – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

About EVAH Corp. 

Standing for Evolution in Animal Health, EVAH is innovating for a better tomorrow. We are a Canada-based biotechnology company with a global perspective. Our team of managers and scientists is acquiring and developing animal health technologies and collaborating with research and development experts to bring them to the pre-commercial stage. We are positioned to respond to global trends in the food-producing animal space and tap growing markets for productivity-enhancing solutions to sustainably feed the world thanks to healthy animal production and address consumer needs for non-antibiotic protein. www.evahcorp.ca.

Contact Corporate Communications

Nicole Blanchard
+ 514-961-0229